盛和資源(600392.SH):擬向激勵對象授予限制性股票總計2300萬股
格隆匯 1 月 18日丨盛和資源(600392.SH)發佈2021年限制性股票激勵計劃(草案),擬向激勵對象授予限制性股票總計2300萬股,佔公吿時公司股本總額的1.3104%。其中首次擬授予限制性股票2300萬股,佔公吿時公司股本總額的1.3104%,佔擬授出限制性股票總數的100%。該激勵計劃沒有預留股票。
該激勵計劃授予的限制性股票的授予價格為5.7元/股。
該激勵計劃首次授予的激勵對象總人數為51人,激勵對象包括公司高級管理人員、子公司董事和高級管理人員、公司及子公司核心技術(業務)人員,以及公司認為應當激勵的對公司經營業績和未來發展有直接影響的關鍵崗位員工。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.